TD Cowen Reiterates Buy Rating on Incyte (INCY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 113.31 -2.4 (2.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.71 | 52 Week High | $118.49 | |||
| Open | $115.49 | 52 Week Low | $55.00 | |||
| Day High | $115.93 | P/E | N/A | |||
| Day Low | $112.75 | EPS | $-0.56 | |||
| Volume | 2,263,996 | |||||
